HIGHLIGHTS
- who: Jeffrey Cummings from the (UNIVERSITY) have published the paper: The “rights” of precision drug development for Alzheimer’s disease, in the Journal: (JOURNAL)
- future: Measurement of CNS levels in non-human primates more closely reflects the human physiology but direct measures of cerebrospinal fluid (CSF) levels in phase 1 human studies are required in a disciplined drug development program.
SUMMARY
Drug development sponsors have developed systematic approaches to drug testing including the "rights" of drug development, the "pillars" of drug development, model-based drug development, and a translational medicine guide . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.